Julia Bohlius1, Kari Bohlke2, Roberto Castelli3, Benjamin Djulbegovic4, Maryam B Lustberg5, Massimo Martino6, Giannis Mountzios7, Namrata Peswani8, Laura Porter9, Tiffany N Tanaka10, Gianluca Trifirò11, Hushan Yang12, Alejandro Lazo-Langner13. 1. University of Bern, Bern, Switzerland. 2. American Society of Clinical Oncology, Alexandria, VA. 3. University of Milan, Milan, Italy. 4. City of Hope, Duarte, CA. 5. Ohio State University, Columbus, OH. 6. Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy. 7. Henry Dunant Hospital Center, Athens, Greece. 8. Advocate Medical Group, Orland Park, IL. 9. Independent Patient Advocate, Washington, DC. 10. UC San Diego Moores Cancer Center, La Jolla, CA. 11. University of Messina, Messina, Italy. 12. Thomas Jefferson University, Philadelphia, PA; and. 13. Western University, London, ON, Canada.
Abstract
PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. METHODS: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations as needed. RESULTS: The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited. RECOMMENDATIONS: ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines.
PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. METHODS: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations as needed. RESULTS: The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited. RECOMMENDATIONS: ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines.
Authors: Johan Vansteenkiste; John Glaspy; David Henry; Heinz Ludwig; Robert Pirker; Dianne Tomita; Helen Collins; Jeffrey Crawford Journal: Lung Cancer Date: 2012-01-25 Impact factor: 5.705
Authors: Giulio Giordano; Patrizia Mondello; Rosa Tambaro; Nicola Perrotta; Fabio D'Amico; Antonietta D'Aveta; Giuseppe Berardi; Bruno Carabellese; Andrea Patriarca; Grazia Maria Corbi; Luigi DI Marzio; Antonietta Licianci; Donata Berardi; Liberato DI Lullo; Roberto DI Marco Journal: Mol Clin Oncol Date: 2015-04-29
Authors: Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: M Untch; G von Minckwitz; G E Konecny; U Conrad; W Fett; C Kurzeder; H-J Lück; E Stickeler; H Urbaczyk; B Liedtke; M W Beckmann; C Salat; N Harbeck; V Müller; M Schmidt; S Hasmüller; M Lenhard; V Nekljudova; A Lebeau; S Loibl; P A Fasching Journal: Ann Oncol Date: 2011-03-07 Impact factor: 32.976
Authors: M Aapro; V Moebus; U Nitz; J O'Shaughnessy; P Pronzato; M Untch; D Tomita; C Bohac; B Leyland-Jones Journal: Ann Oncol Date: 2014-12-26 Impact factor: 32.976
Authors: J Douglas Rizzo; Alan E Lichtin; Steven H Woolf; Jerome Seidenfeld; Charles L Bennett; David Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Stephanie J Lee; Carole B Miller; Mark U Rarick; David H Regan; George P Browman; Michael S Gordon Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Mike J Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Maryann Napoli; Dirk Rades; David Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert Journal: Cochrane Database Syst Rev Date: 2009-07-08
Authors: E Hellström-Lindberg; T Ahlgren; Y Beguin; M Carlsson; J Carneskog; I M Dahl; I Dybedal; G Grimfors; L Kanter-Lewensohn; O Linder; M Luthman; E Löfvenberg; H Nilsson-Ehle; J Samuelsson; J M Tangen; I Winqvist; G Oberg; A Osterborg; A Ost Journal: Blood Date: 1998-07-01 Impact factor: 22.113
Authors: A Toma; O Kosmider; S Chevret; J Delaunay; A Stamatoullas; C Rose; O Beyne-Rauzy; A Banos; A Guerci-Bresler; S Wickenhauser; D Caillot; K Laribi; B De Renzis; D Bordessoule; C Gardin; B Slama; L Sanhes; B Gruson; P Cony-Makhoul; B Chouffi; C Salanoubat; R Benramdane; L Legros; E Wattel; G Tertian; K Bouabdallah; F Guilhot; A L Taksin; S Cheze; K Maloum; S Nimuboma; C Soussain; F Isnard; E Gyan; R Petit; J Lejeune; V Sardnal; A Renneville; C Preudhomme; M Fontenay; P Fenaux; F Dreyfus Journal: Leukemia Date: 2015-10-26 Impact factor: 11.528
Authors: Kyong Hwa Park; Jong Hoon Park; Ah Reum Lim; Jwa Hoon Kim; Myung Han Hyun; Won-Jin Chang; Soohyeon Lee; Yeul Hong Kim Journal: Support Care Cancer Date: 2022-03-11 Impact factor: 3.603
Authors: Tamta Makharadze; Ralph Boccia; Anna Krupa; Nicole Blackman; David H Henry; Jeffrey A Gilreath Journal: Am J Hematol Date: 2021-11-19 Impact factor: 13.265